Responses to Medicare Drug Costs among Near-Poor versus Subsidized Beneficiaries
Objective: There is limited information on the protective value of Medicare Part D low-income subsidies ( LIS).
Objective: There is limited information on the protective value of Medicare Part D low-income subsidies ( LIS).
Background: Relative to traditional fee-for-service Medicare, managed care plans caring for Medicare beneficiaries may be better positioned to promote recommended services and discourage burdensome pr
Geographic variation in per-beneficiary Medicare spending that cannot be explained by wages and the prices of other inputs to health care or by demographic and health characteristics, as described by
We investigate the role of physician agency and competition in determining health care supply and patient outcomes.
Health care in the United States is more expensive than in other developed countries, costing $2.7 trillion in 2011, or 17.9 percent of the national gross domestic product.
With quality-of-care bonus payments now available for Medicare Advantage health maintenance organizations (HMOs) and for accountable care organizations in traditional Medicare, the need to under
Objective: Medicare Part D provides formulary protections for antipsychotics but does not exempt these drugs from cost-sharing.
Identifying policies that will cut or constrain US health care spending and spending growth dominates reform efforts, yet little is known about whether the drivers of spending levels and of spending g
The article focuses on a study which examined the effects of the expanding Medicaid coverage for low-income adults in the U.S. using the 2008 Medicaid expansion in Oregon.
Get smart & reliable public policy insights right in your inbox.